Head-to-head evidence
BGM1812 vs petrelintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin/calcitonin receptor (dual) · full Obesity pipeline
BGM1812
Developed by BrightGene Bio-Medical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
petrelintide
Developed by Zealand Pharma and partners
NCT06662539 · Phase 2 · completed
The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM1812's landscape · petrelintide's landscape